Herbert Loong, Chair-Elect of the International Affairs Committee at American Society of Clinical Oncology (ASCO), shared an article by A.C. Chiang, et al. on LinkedIn:
“Happy to share our recent ESMO Open paper on the safety and feasibility of outpatient administration of tarlatamab as part of the DeLLphi300 study providing evidence that support less intensive monitoring at initiation of therapy.
Luis Paz-Ares, Noemi Reguart, Shirish Gadgeel and others.”
Safety of tarlatamab with 6-8-h outpatient versus 48-h inpatient monitoring during cycle 1: DeLLphi-300 phase 1 substudy.
Authors: A.C. Chiang, et al.
